| Miss Sarah Rani Tandan, NP | |
|
617 Riverside Ave, Burlington, VT 05401 | |
| (802) 864-6309 | |
| (802) 860-4313 |
| Full Name | Miss Sarah Rani Tandan |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 617 Riverside Ave, Burlington, Vermont |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194144741 | NPI | - | NPPES |
| 1030792 | Medicaid | VT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 101-0127573 (Vermont) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | 101.0127573 (Vermont) | Primary |
| Entity Name | University Of Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659309615 PECOS PAC ID: 3779491071 Enrollment ID: O20040406001047 |
News Archive
ViroStatics, a private Italian/American biopharmaceutical company developing novel therapeutics for viral and other chronic diseases, announced that a review of the first human clinical trial to test a new class of anti-HIV medications known as AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs) has been published in the peer-reviewed journal PLoS ONE.
In the largest genetic study of suicide attempts to date, researchers have identified a region of the genome on chromosome 7 containing DNA variations that increase the risk that a person will attempt suicide.
Research conducted through an equitable partnership of the LSTM and its partners (theRESPOND-Africaconsortium), which includes NIMR in Tanzania and MRC/UVRI and LSHTM Uganda Research Unit in Uganda, has found that integrating the care of HIV, diabetes, and hypertension into a 'one-stop clinic' can reduce the costs for both patients and healthcare services in Uganda and Tanzania.
Cell Therapeutics, Inc. today announced that it has entered into an agreement to sell, subject to customary closing conditions, $4.06 million of securities to an accredited investor in a private offering pursuant to Section 4(2) of the Securities Act of 1933, as amended. The securities consist of 4,060 shares of Series 6 preferred stock, no par value per share, together with warrants to purchase an aggregate of 5.8 million shares of common stock (the "Series 6 Financing"). The offering is scheduled to close on or about July 27, 2010, subject to the satisfaction of customary closing conditions.
Promising new viral hepatitis data presented today at the International Liver CongressTM show that entry inhibitors -a new mechanism of action for drugs to treat viral hepatitis - could provide the first new hepatitis B and hepatitis D treatments for many years.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Miss Sarah Rani Tandan, NP 617 Riverside Ave, Burlington, VT 05401-1601 Ph: (802) 864-6309 | Miss Sarah Rani Tandan, NP 617 Riverside Ave, Burlington, VT 05401 Ph: (802) 864-6309 |
News Archive
ViroStatics, a private Italian/American biopharmaceutical company developing novel therapeutics for viral and other chronic diseases, announced that a review of the first human clinical trial to test a new class of anti-HIV medications known as AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs) has been published in the peer-reviewed journal PLoS ONE.
In the largest genetic study of suicide attempts to date, researchers have identified a region of the genome on chromosome 7 containing DNA variations that increase the risk that a person will attempt suicide.
Research conducted through an equitable partnership of the LSTM and its partners (theRESPOND-Africaconsortium), which includes NIMR in Tanzania and MRC/UVRI and LSHTM Uganda Research Unit in Uganda, has found that integrating the care of HIV, diabetes, and hypertension into a 'one-stop clinic' can reduce the costs for both patients and healthcare services in Uganda and Tanzania.
Cell Therapeutics, Inc. today announced that it has entered into an agreement to sell, subject to customary closing conditions, $4.06 million of securities to an accredited investor in a private offering pursuant to Section 4(2) of the Securities Act of 1933, as amended. The securities consist of 4,060 shares of Series 6 preferred stock, no par value per share, together with warrants to purchase an aggregate of 5.8 million shares of common stock (the "Series 6 Financing"). The offering is scheduled to close on or about July 27, 2010, subject to the satisfaction of customary closing conditions.
Promising new viral hepatitis data presented today at the International Liver CongressTM show that entry inhibitors -a new mechanism of action for drugs to treat viral hepatitis - could provide the first new hepatitis B and hepatitis D treatments for many years.
› Verified 3 days ago
Ms. Maureen Louise Dwyer, NURSE PRACTITIONER Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: Mcclure 5 Fletcherallen Healthcare, 111colchester Ave, Burlington, VT 05401 Phone: 802-847-2804 Fax: 802-847-2806 | |
Ms. Merja Cahoon, NNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-2370 | |
Brooke Hopkins Ryba, MSN, RN, WHNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-0000 | |
Patricia Manion, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 300 Flynn Ave, Burlington, VT 05401 Phone: 802-488-6200 Fax: 802-488-6919 | |
Erin Michelle Leighton, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1205 North Ave, Burlington, VT 05408 Phone: 802-863-1313 | |
Kayleigh Martincic, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 128 Lakeside Ave, Burlington, VT 05401 Phone: 802-657-7000 | |
Mrs. Susan Albertini White, NURSE PRACTITIONER Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-4589 |